RevitalVision announced the publication of positive clinical data for its digital therapeutic treatment for infantile nystagmus in the British Journal of Ophthalmology. According to a company press release, the study provides the first randomized controlled evidence that RevitalVision, an FDA-cleared neuroplasticity-based visual training program, can improve visual function in patients with infantile nystagmus, a congenital eye movement disorder present from early infancy, characterized by involuntary, rhythmic oscillations of the eyes. 

Read the full article here.